Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
211 hedge funds and large institutions have $4.13B invested in Apellis Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 100 increasing their positions, 53 reducing their positions, and 31 closing their positions.
150% more call options, than puts
Call options by funds: $55.6M | Put options by funds: $22.3M
89% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 53
10% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 31
0.44% less ownership
Funds ownership: 86.48% → 86.04% (-0.44%)
0% less funds holding
Funds holding: 212 → 211 (-1)
9% less capital invested
Capital invested by funds: $4.55B → $4.13B (-$420M)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$39.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$36.2M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$27.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$26.9M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$20.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$121M |
| 2 |
PA
Perceptive Advisors
New York
|
-$52.9M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$28.6M |
| 4 |
Jennison Associates
New York
|
-$18.5M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$12.7M |
APLS Hedge Fund Activity: Q2 2022 in Review
211 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2022, worth a combined $4.13B — down 9.2% from $4.55B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new APLS positions and 31 closed out — a net gain of 3 holders — while 100 added to existing stakes and 53 trimmed.
The largest buyer was BlackRock, adding an estimated $39.9M. The largest seller was Wellington Management Group, cutting an estimated $121M.
- 211 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2022, down from 212 in Q1 2022.
- Funds reported $4.13B of Apellis Pharmaceuticals stock for Q2 2022, down 9.2% quarter-over-quarter.
- 34 funds opened new Apellis Pharmaceuticals positions in Q2 2022 and 31 closed out, a net change of +3 holders.
- The largest Apellis Pharmaceuticals buyer in Q2 2022 was BlackRock, an estimated $39.9M added.
- The largest Apellis Pharmaceuticals seller in Q2 2022 was Wellington Management Group, an estimated $121M sold.
Based on aggregated 13F filings for Q2 2022.